vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and monday.com Ltd. (MNDY). Click either name above to swap in a different company.
monday.com Ltd. is the larger business by last-quarter revenue ($704.0M vs $359.9M, roughly 2.0× AdvanSix Inc.). monday.com Ltd. runs the higher net margin — 1.3% vs -0.8%, a 2.1% gap on every dollar of revenue. monday.com Ltd. produced more free cash flow last quarter ($224.6M vs $36.1M).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Monday.com Ltd. is an Israeli-based cloud-based platform that allows users to create their own applications and project management software. The product was launched in 2014 and in July 2019, the company raised $150 million, based on a $1.9 billion valuation. The company went public in June 2021 and is based in Tel Aviv, Israel.
ASIX vs MNDY — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $704.0M |
| Net Profit | $-2.8M | $9.4M |
| Gross Margin | 7.6% | 89.6% |
| Operating Margin | -0.7% | -4.4% |
| Net Margin | -0.8% | 1.3% |
| Revenue YoY | 9.4% | — |
| Net Profit YoY | -892.9% | — |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | — | ||
| Q3 25 | $374.5M | $704.0M | ||
| Q2 25 | $410.0M | $453.0M | ||
| Q1 25 | $377.8M | $216.9M | ||
| Q4 24 | $329.1M | — | ||
| Q3 24 | $398.2M | $527.1M | ||
| Q2 24 | $453.5M | $337.9M | ||
| Q1 24 | $336.8M | $162.3M |
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-2.6M | $9.4M | ||
| Q2 25 | $31.4M | $21.4M | ||
| Q1 25 | $23.3M | $7.1M | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $-14.2M | ||
| Q2 24 | $38.9M | $-21.7M | ||
| Q1 24 | $-17.4M | $-14.7M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | 89.6% | ||
| Q2 25 | 14.3% | 89.6% | ||
| Q1 25 | 14.2% | 89.2% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | 89.0% | ||
| Q2 24 | 17.9% | 89.2% | ||
| Q1 24 | 0.9% | 89.5% |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.9% | -4.4% | ||
| Q2 25 | 7.7% | -0.7% | ||
| Q1 25 | 7.7% | -2.3% | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | 7.5% | -7.1% | ||
| Q2 24 | 11.5% | -10.3% | ||
| Q1 24 | -7.0% | -14.0% |
| Q4 25 | -0.8% | — | ||
| Q3 25 | -0.7% | 1.3% | ||
| Q2 25 | 7.7% | 4.7% | ||
| Q1 25 | 6.2% | 3.3% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | -2.7% | ||
| Q2 24 | 8.6% | -6.4% | ||
| Q1 24 | -5.2% | -9.0% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $1.15 | — | ||
| Q1 25 | $0.86 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.82 | — | ||
| Q2 24 | $1.43 | — | ||
| Q1 24 | $-0.65 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $1.4B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $1.0B |
| Total Assets | $1.7B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | — | ||
| Q3 25 | $23.7M | $1.4B | ||
| Q2 25 | $18.4M | $1.7B | ||
| Q1 25 | $8.3M | $1.4B | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $17.3M | $1.1B | ||
| Q2 24 | $12.1M | $1.3B | ||
| Q1 24 | $20.6M | $1.1B |
| Q4 25 | $815.2M | — | ||
| Q3 25 | $818.2M | $1.0B | ||
| Q2 25 | $823.7M | $1.2B | ||
| Q1 25 | $794.4M | $1.0B | ||
| Q4 24 | $774.6M | — | ||
| Q3 24 | $766.4M | $813.5M | ||
| Q2 24 | $746.6M | $910.1M | ||
| Q1 24 | $713.2M | $813.5M |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $2.0B | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.5B | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $234.4M |
| Free Cash FlowOCF − Capex | $36.1M | $224.6M |
| FCF MarginFCF / Revenue | 10.0% | 31.9% |
| Capex IntensityCapex / Revenue | 7.7% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 25.02× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $608.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | — | ||
| Q3 25 | $26.6M | $234.4M | ||
| Q2 25 | $21.1M | $147.7M | ||
| Q1 25 | $11.4M | $92.0M | ||
| Q4 24 | $64.2M | — | ||
| Q3 24 | $57.3M | $156.9M | ||
| Q2 24 | $50.2M | $90.3M | ||
| Q1 24 | $-36.2M | $42.7M |
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | $224.6M | ||
| Q2 25 | $-7.2M | $141.8M | ||
| Q1 25 | $-22.6M | $90.5M | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | $151.4M | ||
| Q2 24 | $16.7M | $85.6M | ||
| Q1 24 | $-71.6M | $39.2M |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | 31.9% | ||
| Q2 25 | -1.7% | 31.3% | ||
| Q1 25 | -6.0% | 41.7% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | 28.7% | ||
| Q2 24 | 3.7% | 25.3% | ||
| Q1 24 | -21.3% | 24.1% |
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | 1.4% | ||
| Q2 25 | 6.9% | 1.3% | ||
| Q1 25 | 9.0% | 0.7% | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | 1.0% | ||
| Q2 24 | 7.4% | 1.4% | ||
| Q1 24 | 10.5% | 2.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 25.02× | ||
| Q2 25 | 0.67× | 6.91× | ||
| Q1 25 | 0.49× | 12.99× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
MNDY
Segment breakdown not available.
